TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17713337
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish (Duraphat) applied twice-yearly at school for 26 months
Study: 14604835
Drug: New treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatments to reduce expansion rate by >50%
Study: 14604835
Drug: Statins as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins as a proposed treatment
Study: 12439840
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment for 6 months
Study: 12439840
Drug: Steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids and azathioprine
Study: 12439840
Drug: Steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids and cyclophosphamide
Study: 10353328
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg folic acid
Study: 10353328
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg vitamin B6
Study: 10353328
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.3 mg folic acid and 120 mg vitamin B6
Study: 10353328
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg folic acid
Study: 1934661
Drug: D +
Normalized name: Liver Desiccated + B
Approvals — FDA: no, EMA: no, PMDA: no
Description: D + W (dipyridamole and low-dose warfarin)
Study: 1934661
Drug: Original treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original treatment group (27 patients)
Study: 1934661
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment group (n = 13)
Study: 6119937
Drug: pindolol (beta-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol (beta-blocker with intrinsic sympathomimetic activity)
Study: 6119937
Drug: beta-blockers without
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blockers without intrinsic sympathomimetic activity
Study: 31987567
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (resting for 2 minutes without treatment)
Study: 28800211
Drug: Generic dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic dofetilide 0.5 mg
Study: 24840659
Drug: Nighttime bending
Normalized name: Flonase Nighttime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nighttime bending brace treatment
Study: 2066441
Drug: Tetracycline-immobilized cross-linked
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline-immobilized cross-linked collagen film (TC film) administered 4 times at 1-week intervals
Study: 2066441
Drug: Root planing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root planing (RP) treatment
Study: 2066441
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (TC + RP)
Study: 6367861
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of adjuvant chemotherapy with CMF
Study: 6367861
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of adjuvant chemotherapy with CMF
Study: 6367861
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of CMF preceded by local-regional x-ray therapy (XRT)
Study: 6367861
Drug: XRT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: XRT treatment arm
Study: 31601357
Drug: RAFT -
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAFT - group cognitive-behavioural therapy (CBT) programme delivered by rheumatology tutor pairs (nurses/occupational therapists)
Study: 30373553
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L Physioneal 1.36% glucose dialysis fluid
Study: 30373553
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L Physioneal 3.86% glucose dialysis fluid
Study: 24527531
Drug: On-time dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-time dosing of tadalafil (10 mg/20 mg, twice a week for 8 weeks)
Study: 24527531
Drug: On-demand dosing
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On-demand dosing of tadalafil (10 mg/20 mg before sexual activity)
Study: 22205307
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg n-3 LCPUFAs as a supplement per day and a concomitant reduction in arachidonic acid intake
Study: 20970603
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily prolonged-release tacrolimus (QD)
Study: 20970603
Drug: Twice-daily tacrolimus
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily tacrolimus (BID)
Study: 16366757
Drug: Caffeine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 2.5 mg/kg p.o.
Study: 16366757
Drug: Caffeine 5.0
Normalized name: CAFFEINE 5.0 mg in 1000 mL TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 5.0 mg/kg p.o.
Study: 11923693
Drug: Everolimus 0.75
Normalized name: everolimus 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 0.75 mg bid
Study: 11923693
Drug: Everolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 1.5 mg bid
Study: 2658177
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg intravenously every 6 hours for 72 hours)
Study: 2658177
Drug: No ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ranitidine treatment (control group)
Study: 6113060
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment control
Study: 28280731
Drug: Tapered implant
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tapered implant with knife‐edge threads/nanostructured calcium‐incorporated surface (Anyridge®, Megagen)
Study: 28280731
Drug: Cylindrical implant
Normalized name: Imperata cylindrica root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylindrical implant with self‐tapping threads/sandblasted surface (EZPlus®, Megagen)
Study: 23663579
Drug: Tirofiban and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban and warfarin combined with aspirin and clopidogrel (observation group)
Study: 22975664
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel (control group)
Study: 21410840
Drug: Misoprostol moistened
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol moistened with normal saline solution (NSS)
Study: 19462302
Drug: Sublingual nicotine
Normalized name: nicotine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nicotine replacement therapy (NRT)
Study: 11494629
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) consisting of conjugated equine estrogens and medroxyprogesterone acetate (MPA)
Study: 8483425
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogens (CEE) 0.625 mg/day over a 25‐day cycle each month (n = 28)
Study: 8483425
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐oestradiol 50 micrograms/day over a 24‐day cycle each month (n = 28)
Study: 8483425
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/day every day of the month (n = 32)
Study: 8483425
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n = 30)
Study: 3087619
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with Tegafur
Study: 26593273
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of cTBS+iTBS, 1800 pulses/session for each
Study: 22238630
Drug: DA medication
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA medication ON condition
Study: 22238630
Drug: DA medication
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA medication OFF condition
Study: 19009290
Drug: Whole-body low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Whole-body low-dose computed tomography (WBLDCT)
Study: 7653443
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy (group 3b)
Study: 59787
Drug: Subunit vaccines
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccines containing hemagglutinin, neuraminidase, and nucleocapsids of A/Port Chalmers/1/73 (H3N2) influenza virus
Study: 59787
Drug: Booster doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster doses of antigen
Study: 59787
Drug: Intact influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact influenza B virus vaccine
Study: 59787
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of the subunit vaccines (1,400 chick cell‐agglutinating units)
Study: 19646194
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg rosiglitazone
Study: 15504990
Drug: Insulin (premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (premixed 70/30)
Study: 11182215
Drug: Cilostazol (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100-200 mg, two or four times daily for 12 months)
Study: 2903602
Drug: Spasmofen (narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spasmofen (narcotic combination drug)
Study: 19231774
Drug: Intraoperative cone-beam
Normalized name: Pinus strobus cone extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative cone-beam computed tomography using a mobile isocentric C-arm (PowerMobil; Siemens Medical Solutions) with different tube currents (4.6 mA, 3.3 mA, 2.3 mA, 1.2 mA, and 0.5 mA) and a current tube voltage of 100 kV
Study: 12480288
Drug: Granules containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granules containing 40% MCCh with ibuprofen
Study: 3556257
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg povidone-iodine pessaries, taken twice daily for five consecutive days
Study: 3556257
Drug: Placebo pessaries,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pessaries, taken twice daily for five consecutive days
Study: 18823487
Drug: Topical Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Lactobacillus casei rhamnosus (Lcr35) vaginal capsules (10^9 CFU) for 7 days after antibiotic treatment
Study: 18823487
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic therapy for 7 days
Study: 11127762
Drug: estradiol 50
Normalized name: estradiol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradiol 50 mg (E)
Study: 11127762
Drug: estradiol 50
Normalized name: estradiol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradiol 50 mg plus testosterone 50 mg implants (E&T)
Study: 8708167
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 300 mg loading dose followed by continuous infusion of 1.2 mg/kg per h for 5 days
Study: 27358417
Drug: Fe‐Beans (86
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe‐Beans (86 mg Fe/kg), consumed 2 times/d for 128 days
Study: 27358417
Drug: Control‐Beans (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control‐Beans (50 mg Fe/kg), consumed 2 times/d for 128 days
Study: 23860793
Drug: Coated implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated implant
Study: 23860793
Drug: Uncoated implant
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uncoated implant
Study: 18784532
Drug: Nonresorbable membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresorbable membrane used to seal the lateral access window of the maxillary sinus after implant placement in 5 cases (group A)
Study: 12552040
Drug: milameline (muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: milameline (muscarinic receptor agonist)
Study: 10372249
Drug: Acarbose (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (n = 973, max dose 100 mg three times per day)
Study: 8665111
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose solution with 3 MBq of 99mtechnetium labelled DTPA
Study: 8665111
Drug: iso‐osmotic maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: iso‐osmotic maltodextrin solution with 3 MBq of 99mtechnetium labelled DTPA
Study: 8665111
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of gastric emptying rates between glucose and maltodextrin solutions
Study: 8450107
Drug: Behavioral Marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Marital Therapy (BMT)
Study: 2002129
Drug: Insight-Oriented Marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insight-Oriented Marital Therapy (IOMT)
Study: 22327894
Drug: Contour Profile
Normalized name: mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contour Profile Gel breast implants
Study: 9565933
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) 0.3 g.kg‐1
Study: 31911526
Drug: Tailored pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored pharmacist intervention including reminders, habit-based strategies, family support, counselling, and strategies to address drug-related problems.
Study: 25628348
Drug: Endoscopic balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic balloon dilation with steroid injection
Study: 25628348
Drug: Radial incision
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radial incision and cutting with steroid injection
Study: 23361846
Drug: Ticlopidine (CYP2B6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (CYP2B6 inhibitor), given orally for 4 days
Study: 21809126
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (common needling on Zusanli (ST36), electroacupuncture on Sanyinjiao (SP6), Shuidao (ST28), and Scalp Reproduction Area, moxibustion on Shenque (CV8))
Study: 21809126
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection with vitamin B12 at Sanyinjiao and Zusanli
Study: 21809126
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection with vitamin B12
Study: 17903567
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group conclusions favoring treatment efficacy
Study: 15638817
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 g daily for 3 weeks)
Study: 9894821
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg d(‐1) syrup with multivitamin (2 x RDA))
Study: 7659481
Drug: Whole-cell pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell pertussis vaccine (WCL)
Study: 2568805
Drug: Iotrolan 280
Normalized name: iotrolan 280 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iotrolan 280 (0.15 to 0.9 g I/kg body weight)
Study: 2568805
Drug: Iotrolan 280
Normalized name: iotrolan 280 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iotrolan 280 (0.9 g I/kg body weight)
Study: 29569351
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (3 times a week for 4 weeks)
Study: 21393644
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy combined with standard therapy (TENS, ultrasound therapy, kinesiotherapy)
Study: 21393644
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (TENS, ultrasound therapy, kinesiotherapy)
Study: 10803671
Drug: Iodixanol 270
Normalized name: IODIXANOL 270mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 270 mg I/mL
Study: 10803671
Drug: Iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 300 mg I/mL
Study: 9032862
Drug: Gamma Knife
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma Knife treatment
Study: 1909637
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg b.i.d.
Study: 1909637
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg b.i.d. plus 4 g cholestyramine o.d.
Study: 6614958
Drug: 5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% fluorouracil cream applied daily to vitiliginous lesions under occlusive dressings
Study: 6614958
Drug: 5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% fluorouracil cream
Study: 17609842
Drug: Horizontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horizontal therapy (HT)
Study: 17609842
Drug: Sham horizontal
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham horizontal therapy (Control)
Study: 7567311
Drug: Ceftibuten 9
Normalized name: ceftibuten 90 MG in 5 mL Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 9 mg/kg once daily (max 400 mg)
Study: 7567311
Drug: Cefaclor 40
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor 40 mg/kg/day in three divided doses (max 1 g/day)
Study: 2095647
Drug: Immunoglobulin preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin preparation (Pentaglobin) administered intravenously
Study: 7272608
Drug: Guided mourning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided mourning treatment (facing cues concerning bereavement)
Study: 7272608
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (avoiding cues concerning bereavement)
Study: 29030864
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate 0·015% gel
Study: 24501015
Drug: telehealth problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telehealth problem-solving therapy (tele-PST via Skype video call)
Study: 24501015
Drug: in-person problem-solving
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: in-person problem-solving therapy (PST)
Study: 22819575
Drug: Intraperitoneal lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal lignocaine (20 ml of 0.5% lignocaine)
Study: 22819575
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml of isotonic saline)
Study: 20045576
Drug: IV prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV prochlorperazine with 12.5 mg diphenhydramine
Study: 12464140
Drug: G. biloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. biloba extract (Gibidyl Forte(R))
Study: 7657737
Drug: Zoladex depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex depot (single injection)
Study: 7657737
Drug: Suprefact (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprefact (multiple daily injections)
Study: 25162967
Drug: Low-dose metformin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metformin (250 mg/day)
Study: 25162967
Drug: Middle-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-dose metformin (500 mg/day)
Study: 25162967
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin (1500 mg/day)
Study: 25162967
Drug: Control (untreated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (untreated with metformin)
Study: 23486306
Drug: Standard Su‐Per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Su‐Per treatment
Study: 23486306
Drug: Su‐Per treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Su‐Per treatment without higher stimulus at interspinous line
Study: 19513760
Drug: Metamizole (3x1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizole (3x1000 mg)
Study: 11752508
Drug: Corticosteroids (Cs)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (Cs) treatment
Study: 11752508
Drug: No corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No corticosteroids (Cs) treatment
Study: 10876967
Drug: Oral natural
Normalized name: Nature-Throid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral natural alpha‐Interferon (OROFERONE‐IFI) at 150U tid for 8 weeks
Study: 8880052
Drug: Deflazacort (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort (12 mg, 30 mg, 60 mg)
Study: 8880052
Drug: Prednisolone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (8 mg, 20 mg, 40 mg)
Study: 2068049
Drug: L-acetyl carnitine
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetyl carnitine (1.5 g, intravenously)